Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome--a comparative observational study. The Canadian Streptococcal Study Group.

@article{Kaul1999IntravenousIT,
  title={Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome--a comparative observational study. The Canadian Streptococcal Study Group.},
  author={Rajat Kaul and Allison Mcgeer and Anna Norrby-Teglund and Malak Kotb and Benjamin E. Schwartz and Killian E T O'Rourke and James Talbot and Donald Edward Low},
  journal={Clinical infectious diseases : an official publication of the Infectious Diseases Society of America},
  year={1999},
  volume={28 4},
  pages={800-7}
}
Twenty-one consecutive patients with streptococcal toxic shock syndrome (TSS) between December 1994 and April 1995 were treated with a median dose of 2 g of intravenous immunoglobulin (IVIG)/kg (cases) and were compared with 32 patients with streptococcal TSS between 1992 and 1995 who did not receive IVIG therapy (controls). The outcome measure was 30-day survival. Patient plasma was tested for its ability to inhibit T cell activation induced by the infecting strain. The proportion of cases… CONTINUE READING